CRCT1 and breast cancer: These observations are in line with our analyses with respect to the co-amplification of HRNR, CRCT1, KPRP, and FLG2 across all the major BC categories; however, we could not demonstrate an enrichment of either BC progression (disease-free survival/DFS) or mortality (overall survival status) in BC with the amplification (Figure 2A).